SCHEMBL2644082

SCHEMBL2644082

CC1(C)Cc2c(Oc3ccc(C(=N)NO)c(F)c3)cc(C(=O)O)cc2O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 3/20 0.53
FFAR4 Q5NUL3 2/20 0.35
EZH2 Q15910 1/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
GAA P10253 3/20 0.34
LPAR1 Q92633 2/20 0.34
LPAR5 Q9H1C0 2/20 0.34
HPGD P15428 2/20 0.34
CASP1 P29466 2/20 0.34
HSD17B10 Q99714 2/20 0.34
GLA P06280 1/20 0.34
CASP7 P55210 1/20 0.34
HIF1A Q16665 1/20 0.32
RXRA P19793 4/20 0.32
RARB P10826 2/20 0.32
RARG P13631 2/20 0.32
RARA P10276 1/20 0.32
CPS1 P31327 1/20 0.32
S1PR2 O95136 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644137 0.89 GCK (0.44) GCKFFAR4EZH2KDM4EALDH1A1
SCHEMBL2645431 0.87 GCK (0.58) GCKFFAR4EZH2KDM4EALDH1A1
SCHEMBL2643968 0.86 GCK (0.42) GCKFFAR4KDM4EALDH1A1GAA
SCHEMBL2643938 0.86 GCK (0.59) GCKFFAR4EZH2KDM4EALDH1A1
SCHEMBL644377 0.85 GCK (0.52) GCKFFAR4EZH2KDM4EALDH1A1
SCHEMBL2644107 0.85 GCK (0.56) GCKFFAR4EZH2KDM4EALDH1A1
SCHEMBL2644938 0.84 GCK (0.55) GCKFFAR4EZH2ALDH1A1LPAR1
SCHEMBL643947 0.84 GCK (0.51) GCKFFAR4EZH2KDM4EALDH1A1
SCHEMBL2644769 0.83 GCK (0.56) GCKFFAR4EZH2ALDH1A1LPAR1
SCHEMBL2643748 0.83 GCK (0.54) GCKFFAR4EZH2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885FFAR4 1693/4885EZH2 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.